Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. (Q37825946)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

cardiovascular disease

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

P Anagnostis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

F Adamidou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Panagiotou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Kita

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Karagiannis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

D P Mikhailidis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

302-312

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

Defining and characterizing the progression of type 2 diabetes

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Mining incretin hormone pathways for novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Exenatide: a review from pharmacology to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The pathobiology of diabetic complications: a unifying mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Myocardial protection at a crossroads: the need for translation into clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Role of glycogen synthase kinase-3beta in cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Endothelial dysfunction in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Endothelium-dependent vasodilation in conduit and resistance vessels in relation to the endothelial nitric oxide synthase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The role of carotid arterial intima-media thickness in predicting clinical coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Should adipokines be considered in the choice of the treatment of obesity-related health problems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Postprandial lipid metabolism in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01345.X

10.1111/J.1463-1326.2010.01345.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205117%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference